Abstract
During the roll out of vaccines during a pandemic, questions regarding vaccine safety often arise. This was surely true during the SARS-CoV-2 pandemic. Different tools and capabilities exist during the pre-authorization phase and post introduction each with its strengths and limitations. Here we review the various tools and their strengths and limitations and discuss what functioned well in high income settings and the limitations that unequal vaccine safety pharmacovigilance capacity imposed upon middle and low income countries.
Original language | English |
---|---|
Pages (from-to) | 3790-3795 |
Number of pages | 6 |
Journal | Vaccine |
Volume | 41 |
Issue number | 25 |
DOIs | |
Publication status | Published - 7 Jun 2023 |
Keywords
- COVID-19/prevention & control
- Humans
- Pandemics/prevention & control
- Pharmacovigilance
- SARS-CoV-2
- Vaccines/adverse effects